mProX™ Human PRKCA Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human PRKCA Stable Cell Line (S01YF-1023-PY61). Click the button above to contact us or submit your feedback about this product.
Peyton Williams (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Alex Smith (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Inhibition of breast cancer cell line growth was achieved through the co-delivery of siRNA targeting PRKCA and a PTEN plasmid.
The assessment of cell viability was conducted by evaluating the delivery of PRKCA siRNA and PTEN plasmid in MCF-7, MDA-MB-231, and 4T1 cells through the administration of PRKCA+NPs, PTEN+NPs, and PRKCA+PTEN+NPs formulations over a 48-hour period. The experiments were repetitively carried out three times within each cell line, and the values were expressed as the mean ± SD of triplicates in the MTT assay. Significantly reduced cell viability (p < 0.05) was observed in cells treated with PRKCA+PTEN+NPs compared to those treated with PRKCA+NPs and/or PTEN+NPs.
Ref: Ibnat, Nabilah, Rowshan Ara Islam, and Ezharul Hoque Chowdhury. "Inhibition of breast tumour growth with intravenously administered PRKCA siRNA-and PTEN tumour suppressor gene-loaded carbonate apatite nanoparticles." Applied Sciences 11.17 (2021): 8133.
Pubmed: NA
DOI: 10.3390/app11178133
Research Highlights
Yu, Chenyang. et al. "Exploration of potential targets and mechanisms of naringenin in the treatment of nonalcoholic fatty liver disease through network pharmacology." Medicine, 2023.
In this study, the molecular mechanisms and potential targets of naringenin (NR) for the treatment of nonalcoholic fatty liver disease (NAFLD) were investigated using network pharmacology. Naringenin targets and NAFLD-related targets were screened, yielding 89 shared targets and 16 core targets. GO enrichment analysis revealed 176 significant GO terms, including biological processes, cell composition, and molecular functions. Kyoto encyclopedia of genes and genomes pathway analysis identified 137 relevant pathways. The core targets for NR in NAFLD treatment included TP53, CASP3, PRKCA, AKT1, RELA, PPARG, NCOA2, CYP1A1, ESR1, MAPK3, STAT3, JAK1, MAPK1, TNF, PPARA, and PRKCB. These findings suggest that NR exerts its therapeutic effects on NAFLD through multiple targets and pathways, providing a foundation for future drug development and clinical trials.
Yu, Chenyang. et al. "Exploration of potential targets and mechanisms of naringenin in the treatment of nonalcoholic fatty liver disease through network pharmacology." Medicine, 2023.
Pubmed:
37861538
DOI:
10.1097/MD.0000000000035460
Guang, Biao. et al. "Dissection of action mechanisms of Zuogui Pill in the treatment of liver cancer based on machine learning and network pharmacology: A review." Medicine, 2023.
In this study, an exploration of the mechanism by which Zuogui Pill is effective in treating liver cancer was undertaken using data mining and network pharmacology methods. A novel clustering analysis algorithm was employed to identify 5 core modules of Zuogui Pill. Ten key target proteins, including FOS, PTGS2, and MYC, were identified through the use of the GEO platform. Significant enrichments in various biological processes, particularly in MAPK and PI3K-Akt signaling pathways, were observed through GO annotation and KEGG analysis. Strong binding affinities between the active ingredients of Zuogui Pill and these key targets were revealed via molecular docking, with the highest affinities observed for PTGS2-Sesamin, PRKCA-Sesamin, and FOS-delta-Carotene. A heterogeneous targets-related network was constructed, establishing 60 key target-symptom associations. The study suggests that therapeutic potential for liver cancer exists in Zuogui Pill through its network of targets and the synergistic effects of multiple components and pathways, offering valuable insights into its underlying molecular mechanisms for future reference in experiments, requiring less time and effort.
Guang, Biao. et al. "Dissection of action mechanisms of Zuogui Pill in the treatment of liver cancer based on machine learning and network pharmacology: A review." Medicine, 2023.
Pubmed:
37861529
DOI:
10.1097/MD.0000000000035628
